Li Youping, Yu Jiajie, Du Liang, Sun Xin, Kwong Joey S W, Wu Bin, Hu Zhiqiang, Lu Jing, Xu Ting, Zhang Lingli
Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China.
Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, China.
J Evid Based Med. 2015 Nov;8(4):222-8. doi: 10.1111/jebm.12181.
After 38 years of development, the procedure of selection and evaluation of the World Health Organization Essential Medicine List (WHO EML) is increasingly scientific and formal. However, peer review for the applications of World Health Organization Essential Medicine List is always required in a short period. It is necessary to build up a set of methods and processes for rapid review.
We identified the process of evidenced-based rapid review on WHO EML application for peer reviews according to 11 items which were required during reporting of the peer review results of the proposals.
The most important items for the rapid review of World Health Organization Essential Medicine List peer reviewers are (1) to confirm the requirements and identify the purposes; (2) to establish the research questions and translate the questions into the 'Participants, Interventions, Comparators, Outcomes, Study design' (PICOS) format; (3) to search and screen available evidence, for which high-level evidence is preferred, such as systematic reviews or meta-analyses, health technology assessment, clinical guidelines; (4) to extract data, where we extract primary information based on the purposes; (5) to synthesize data by qualitative methods, assess the quality of evidence, and compare the results; (6) to provide the answers to the applications, quality of evidences and strength of recommendations.
Our study established a set of methods and processes for the rapid review of World Health Organization Essential Medicine List peer review, and our findings were used to guide the reviewers to fulfill the 19(th) World Health Organization Essential Medicine List peer review. The methods and processes were feasible and met the necessary requirements in terms of time and quality. Continuous improvement and evaluation in practice are warranted.
经过38年的发展，世界卫生组织基本药物清单（WHO EML）的遴选和评估程序日益科学和规范。然而，对世界卫生组织基本药物清单申请的同行评审总是需要在短时间内完成。有必要建立一套快速评审的方法和流程。
根据提案同行评审结果报告中要求的11项内容，确定了基于证据的世界卫生组织基本药物清单申请同行评审快速评审流程。
世界卫生组织基本药物清单同行评审快速评审最重要的内容包括：（1）确认要求并明确目的；（2）提出研究问题并将问题转化为“参与者、干预措施、对照、结局、研究设计”（PICOS）格式；（3）检索和筛选可用证据，优先选择高级别证据，如系统评价或Meta分析、卫生技术评估、临床指南；（4）提取数据，即根据目的提取主要信息；（5）采用定性方法综合数据，评估证据质量并比较结果；（6）提供申请的答案、证据质量和推荐强度。
我们的研究建立了一套世界卫生组织基本药物清单同行评审快速评审的方法和流程，研究结果用于指导评审人员完成第19版世界卫生组织基本药物清单同行评审。这些方法和流程可行，在时间和质量方面满足必要要求。在实践中需要不断改进和评估。
